Form 4: Centessa Pharma Exec Sells Shares Under 10b5-1 Plan

Centessa Pharmaceuticals plc President of Orexin Program, Mario Alberto Accardi, sold a total of 10,000 ordinary shares on December 9, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Mario Alberto Accardi, President, Orexin Program at Centessa Pharmaceuticals plc, reported the sale of ordinary shares.
• On December 9, 2025, a total of 10,000 ordinary shares were disposed of in two separate transactions.
• The first transaction involved 7,432 shares sold at a weighted average price of $28.698 per share, with prices ranging from $28.43 to $28.9575.
• The second transaction involved 2,568 shares sold at a weighted average price of $29.2077 per share, with prices ranging from $29.015 to $29.50.
• All sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Accardi on February 14, 2025.
• Following these transactions, Mr. Accardi beneficially owns 178,801 ordinary shares of Centessa Pharmaceuticals plc.

Sentiment

Score: 5

Explanation: The insider sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates a planned financial event rather than a reaction to new company-specific information. This mitigates potential negative sentiment often associated with insider selling.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, adopted on February 14, 2025, which indicates the transactions were pre-scheduled and not based on new material non-public information.

Negatives

• Mario Alberto Accardi, President of the Orexin Program, disposed of 10,000 ordinary shares of Centessa Pharmaceuticals plc.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the insider sale, but the execution under a Rule 10b5-1 plan typically mitigates concerns regarding management's confidence in the company's immediate future, as it suggests a pre-planned financial decision rather than a reaction to new information.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, insider trading, Form 4, stock sale, Mario Alberto Accardi, 10b5-1 plan, ordinary shares, executive compensation